This section provides a wealth of useful information and practical items for both healthcare professionals and patients relating to the management of systemic juvenile idiopathic arthritis (sJIA) and the use of ACTEMRA/RoACTEMRA.
There are a number of materials within this section of the website that provide information regarding the use of ACTEMRA/RoACTEMRA in patients with sJIA. This information includes prescribing information, healthcare professional brochure, dosing and administration guide, dosing poster and macrophage activation syndrome (MAS) summary card. A patient information brochure and patient alert card have been also developed for patients and the parents/guardians of children treated with ACTEMRA/RoACTEMRA. This material can be downloaded for you to share with your patients.
This brochure contains important efficacy and safety information to assist healthcare professionals in assessing the benefits and risks associated with ACTEMRA/RoACTEMRA in patients with sJIA.
This brochure contains detailed safety information on ACTEMRA/RoACTEMRA treatment and a copy may be provided to all patients or parents/guardians to read in their own time.
This guide provides a comprehensive and clear walk-through of how to administer ACTEMRA/RoACTEMRA to patients with sJIA. It includes a dose-calculation chart and full instructions for infusion.
This chart provides an easy wall-mounted reference guide to indicate the quantity of ACTEMRA/RoACTEMRA (and the combination of vial sizes) needed to achieve the recommended dose of 12 mg/kg for patients with a body weight <30 kg and 8 mg/kg for patients with a body weight ≥30 kg.
This pocket-sized card contains a quick reference guide to indicate the quantity of ACTEMRA/RoACTEMRA (and the combination of vial sizes) needed to achieve the recommended dose of 12 mg/kg for patients with a body weight <30 kg and 8 mg/kg for patients with a body weight ≥30 kg.
This pocket-sized card contains key safety information on ACTEMRA/RoACTEMRA that can be carried around by a patient or their parents/guardians and shown to any doctor who may treat them for another condition. Space for recording dates of ACTEMRA/RoACTEMRA treatment is included.
This summary card provides information regarding the complications associated with macrophage activation syndrome in sJIA. This information is important for physicians to understand before commencing ACTEMRA/RoACTEMRA treatment in patients with sJIA.